KYNB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kyntra Bio Inc (KYNB) is not a good buy for a beginner, long-term investor at this time. The technical indicators are bearish, there are no significant trading trends or positive news catalysts, and the company's financial performance shows a sharp decline in net income and EPS despite revenue growth. Additionally, there are no proprietary trading signals or recent congress trading data to support a buy decision.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 32.773, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The pre-market price of 6.885 is near the key support level of 6.787, suggesting limited upside potential in the short term.
Revenue increased significantly by 774.80% YoY in Q3 2025.
Net income dropped by -1274.41% YoY, EPS fell by -1267.29% YoY, and gross margin decreased by -34.53% YoY. No significant trading trends among hedge funds or insiders, and no recent news or congress trading data to act as a catalyst.
In Q3 2025, the company's revenue increased significantly to 1,076,000 (up 774.80% YoY). However, net income dropped sharply to -200,636,000 (-1274.41% YoY), EPS fell to -49.61 (-1267.29% YoY), and gross margin declined to 105.39 (-34.53% YoY).
No data available for analyst ratings or price target changes.
